Articles with the topic: featured

KMO inhibitor drug improves lifespan of Huntington's disease mice

KMO inhibitor drug improves lifespan of Huntington's disease mice

Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice

Professor Ed WildJune 02, 2011

The genetic 'gray area' of Huntington's disease: what does it all mean?

The genetic 'gray area' of Huntington's disease: what does it all mean?

Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained

Dr Nayana LahiriApril 22, 2011

Dimebon fails in late-stage human HD clinical trial

Dimebon fails in late-stage human HD clinical trial

Dimebon fails to improve symptoms in HD patients in the HORIZON trial

Dr Jeff CarrollApril 11, 2011

Gene silencing for HD: the story so far

Gene silencing for HD: the story so far

Is gene silencing as exciting as it sounds for HD, and what might the future hold?

Professor Ed WildMarch 22, 2011

Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis

Interview: Graeme Bilbe, Global Head for Neuroscience at Novartis

HDBuzz interviews Graeme Bilbe, Global Head for Neuroscience at pharmaceutical giant Novartis, about their HD researc

Professor Ed WildMarch 14, 2011

Interview: CHDI Management

Interview: CHDI Management

HDBuzz interviews three top scientists from CHDI, the biggest funder and driver of HD research worldwide

Dr Jeff CarrollFebruary 25, 2011

CHDI Report: Day 3

CHDI Report: Day 3

Day 3 of CHDI’s HD therapeutics conference: growth factors and CHDI’s advanced therapies

Dr Jeff CarrollFebruary 10, 2011

CHDI Report: Day 2

CHDI Report: Day 2

Day 2 of CHDI’s HD therapeutics conference: figuring out energy problems in HD

Professor Ed WildFebruary 09, 2011

CHDI Report: Day 1

CHDI Report: Day 1

Day 1 of CHDI’s HD therapeutics conference: exploring abnormal brain connections and silencing the HD gene

Dr Jeff CarrollFebruary 08, 2011